The CB2R–OX2R heteromer as a new therapeutic target to combat Alzheimer’s disease

Summary of the work awarded with the first prize of the First edition of the UB Dr. Antoni i Subirana Chair Award for Research in Pharmacology for the best Master's Degree in Research in Pharmacology at the University of Barcelona

Detalles Bibliográficos
Autor: Badia Fernàndez, Pau
Tipo de recurso: informe técnico
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:dnet:recercat____::58332d75ac22461fe6887e107453de02
Acceso en línea:https://hdl.handle.net/2445/228684
Access Level:acceso abierto
Palabra clave:Malaltia d'Alzheimer
Farmacologia
Alzheimer's disease
Pharmacology
id ES_12e3859e7dcd3856e51ff6fd7b016f0d
oai_identifier_str oai:dnet:recercat____::58332d75ac22461fe6887e107453de02
network_acronym_str ES
network_name_str España
repository_id_str
spelling The CB2R–OX2R heteromer as a new therapeutic target to combat Alzheimer’s diseaseBadia Fernàndez, PauMalaltia d'AlzheimerFarmacologiaAlzheimer's diseasePharmacologySummary of the work awarded with the first prize of the First edition of the UB Dr. Antoni i Subirana Chair Award for Research in Pharmacology for the best Master's Degree in Research in Pharmacology at the University of BarcelonaAlzheimer’s disease is a severe neurodegenerative disorder that affects approximately 5% of the European population, a percentage that increases substantially among the elderly. It is also the leading cause of dementia in older adults, accounting for more than 60% of cases. Moreover, it affects not only the individual suffering from the disease but also the patient’s environment—family, friends, and acquaintances—resulting in a significant economic burden. For these reasons, Alzheimer’s disease represents a major public health issue, which becomes even more evident considering the ageing of the population.Universitat de Barcelona. Càtedra Dr. Antoni Esteve i Subirana de Recerca en Farmacologia202620262025info:eu-repo/semantics/reportinfo:eu-repo/semantics/publishedVersion5 p.https://hdl.handle.net/2445/228684Premis (Càtedra UB-Dr Antoni Esteve i Subirana de Recerca en Farmacologia)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)Ingléscc by-nc-nd (c) Badia Fernàndez, Pau, 2025http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:dnet:recercat____::58332d75ac22461fe6887e107453de022026-05-29T05:05:01Z
dc.title.none.fl_str_mv The CB2R–OX2R heteromer as a new therapeutic target to combat Alzheimer’s disease
title The CB2R–OX2R heteromer as a new therapeutic target to combat Alzheimer’s disease
spellingShingle The CB2R–OX2R heteromer as a new therapeutic target to combat Alzheimer’s disease
Badia Fernàndez, Pau
Malaltia d'Alzheimer
Farmacologia
Alzheimer's disease
Pharmacology
title_short The CB2R–OX2R heteromer as a new therapeutic target to combat Alzheimer’s disease
title_full The CB2R–OX2R heteromer as a new therapeutic target to combat Alzheimer’s disease
title_fullStr The CB2R–OX2R heteromer as a new therapeutic target to combat Alzheimer’s disease
title_full_unstemmed The CB2R–OX2R heteromer as a new therapeutic target to combat Alzheimer’s disease
title_sort The CB2R–OX2R heteromer as a new therapeutic target to combat Alzheimer’s disease
dc.creator.none.fl_str_mv Badia Fernàndez, Pau
author Badia Fernàndez, Pau
author_facet Badia Fernàndez, Pau
author_role author
dc.subject.none.fl_str_mv Malaltia d'Alzheimer
Farmacologia
Alzheimer's disease
Pharmacology
topic Malaltia d'Alzheimer
Farmacologia
Alzheimer's disease
Pharmacology
description Summary of the work awarded with the first prize of the First edition of the UB Dr. Antoni i Subirana Chair Award for Research in Pharmacology for the best Master's Degree in Research in Pharmacology at the University of Barcelona
publishDate 2025
dc.date.none.fl_str_mv 2025
2026
2026
dc.type.none.fl_str_mv info:eu-repo/semantics/report
info:eu-repo/semantics/publishedVersion
format report
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/228684
url https://hdl.handle.net/2445/228684
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv cc by-nc-nd (c) Badia Fernàndez, Pau, 2025
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by-nc-nd (c) Badia Fernàndez, Pau, 2025
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 5 p.
dc.publisher.none.fl_str_mv Universitat de Barcelona. Càtedra Dr. Antoni Esteve i Subirana de Recerca en Farmacologia
publisher.none.fl_str_mv Universitat de Barcelona. Càtedra Dr. Antoni Esteve i Subirana de Recerca en Farmacologia
dc.source.none.fl_str_mv Premis (Càtedra UB-Dr Antoni Esteve i Subirana de Recerca en Farmacologia)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403642867482624
score 15.81155

Similares en LA Referencia